CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection ...
Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without ...
CROSSJECT (ISIN: FR0011716265; Mnémo: ALCJ), the creator of ZENEO®, a needle free injection system, announces the similarity between the ZENEO® Methotrexate needle-free injection system and the ...
Injection depth with ZENEO® matches that of 30-mm conventional intramuscular needles, out-performs length of needles imbedded in commercially available needle-based auto-injectors. ZENEO® further ...
Dijon, France, November 13, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving ...
Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack ...
CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results